These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37821306)

  • 1. HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study.
    Ghelani GH; Zerdan MB; Jacob J; Spiess PE; Li R; Necchi A; Grivas P; Kamat A; Danziger N; Lin D; Huang R; Decker B; Sokol ES; Cheng L; Pavlick D; Ross JS; Bratslavsky G; Basnet A
    Urol Oncol; 2023 Dec; 41(12):486.e15-486.e23. PubMed ID: 37821306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder.
    Necchi A; Madison R; Raggi D; Jacob JM; Bratslavsky G; Shapiro O; Elvin JA; Vergilio JA; Killian JK; Ngo N; Ramkissoon S; Severson E; Hemmerich AC; Huang R; Ali SM; Chung JH; Reddy P; Miller VA; Schrock AB; Gay LM; Alexander BM; Grivas P; Ross JS
    Eur Urol; 2020 Apr; 77(4):548-556. PubMed ID: 31959546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers.
    Nazha B; Zhuang T; Wu S; Brown JT; Magee D; Carthon BC; Kucuk O; Nabhan C; Barata PC; Heath EI; Ryan CJ; McKay RR; Master VA; Bilen MA
    Cancer; 2023 Dec; 129(24):3884-3893. PubMed ID: 37565840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas.
    Huang RSP; Haberberger J; Harries L; Severson E; Duncan DL; Ferguson NL; Hemmerich A; Edgerly C; Murugesan K; Xiao J; McEwan D; Holmes O; Hiemenz M; Venstrom J; Elvin JA; Creeden J; Lin DI; Ross JS; Ramkissoon SH
    Oncologist; 2021 May; 26(5):375-382. PubMed ID: 33687775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (
    Bou Zerdan M; Ashok Kumar P; Haroun E; Srivastava N; Ross J; Sivapiragasam A
    Oncotarget; 2023 Mar; 14():178-187. PubMed ID: 36913304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study.
    Necchi A; Spiess PE; Bandini M; Basile G; Grivas P; Bratslavsky G; Jacob J; Danziger N; Lin D; Decker B; Sokol ES; Huang RSP; Kulkarni SB; Ross JS
    Oncologist; 2022 Dec; 27(12):1016-1024. PubMed ID: 35881043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel synthetic lethality drug target in urothelial bladder cancer based on MTAP genomic loss.
    Basin MF; Bratslavsky G; Nahhas N; Basnet A; Goldberg H; Necchi A; Sokol ES; Ramkissoon SH; Huang RSP; Ross JS; Jacob JM
    Urol Oncol; 2023 Feb; 41(2):109.e15-109.e22. PubMed ID: 36443178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
    Lee HK; Kwon MJ; Ra YJ; Lee HS; Kim HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Min KW; Kang SY
    Diagn Pathol; 2020 Oct; 15(1):126. PubMed ID: 33054840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Genomic Profiling of NF2-Mutated Kidney Tumors Reveals Potential Targets for Therapy.
    Hacking SM; Pavlick D; Wang Y; Carneiro BA; Mullally M; Lu S; Canepa M; Bratslavsky G; Jacob J; Necchi A; Spiess PE; Wang L; Yakirevich E; Ross J
    Oncologist; 2023 Jul; 28(7):e508-e519. PubMed ID: 36917021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
    Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
    Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
    Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
    Front Immunol; 2021; 12():798424. PubMed ID: 35145511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular events in the pathogenesis of vulvar squamous cell carcinoma.
    Xing D; Fadare O
    Semin Diagn Pathol; 2021 Jan; 38(1):50-61. PubMed ID: 33032902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urothelial Bladder Cancer: Genomic Alterations in Fibroblast Growth Factor Receptor.
    Bou Zerdan M; Bratslavsky G; Jacob J; Ross J; Huang R; Basnet A
    Mol Diagn Ther; 2023 Jul; 27(4):475-485. PubMed ID: 37195586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer.
    Leary JB; Enright T; Bakaloudi DR; Basnet A; Bratslavsky G; Jacob J; Spiess PE; Li R; Necchi A; Kamat AM; Pavlick DC; Danziger N; Huang RSP; Lin DI; Cheng L; Ross J; Talukder R; Grivas P
    Target Oncol; 2024 May; 19(3):447-458. PubMed ID: 38570422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy.
    Kim R; Hong JY; Lee J; Kwon GY; Jeong BC; Park SH
    Cancer Res Treat; 2022 Jul; 54(3):894-906. PubMed ID: 34793662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency.
    Ashok Kumar P; Graziano SL; Danziger N; Pavlick D; Severson EA; Ramkissoon SH; Huang RSP; Decker B; Ross JS
    Cancer Med; 2023 Jan; 12(2):1157-1166. PubMed ID: 35747993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic characterization of vulvar squamous cell carcinoma reveals differential gene expression based on clinical outcome.
    Gordinier ME; Schau GF; Pollock SB; Shields LBE; Talwalkar S
    Gynecol Oncol; 2024 Jan; 180():111-117. PubMed ID: 38086165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
    Seiwert TY; Zuo Z; Keck MK; Khattri A; Pedamallu CS; Stricker T; Brown C; Pugh TJ; Stojanov P; Cho J; Lawrence MS; Getz G; Brägelmann J; DeBoer R; Weichselbaum RR; Langerman A; Portugal L; Blair E; Stenson K; Lingen MW; Cohen EE; Vokes EE; White KP; Hammerman PS
    Clin Cancer Res; 2015 Feb; 21(3):632-41. PubMed ID: 25056374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.
    Ross JS; Wang K; Khaira D; Ali SM; Fisher HA; Mian B; Nazeer T; Elvin JA; Palma N; Yelensky R; Lipson D; Miller VA; Stephens PJ; Subbiah V; Pal SK
    Cancer; 2016 Mar; 122(5):702-11. PubMed ID: 26651075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 expression in anogenital and oropharyngeal squamous cell carcinomas associated with different clinicopathological features, HPV status and prognosis: a meta-analysis.
    Qin Y; Luan J; Zhou X; Li Y
    Biosci Rep; 2021 Mar; 41(3):. PubMed ID: 33704390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.